Arca
Skip to content
Tools
Tools

Huntington disease

Drug research and approvals for huntington disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 41 studies of huntington disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 34 drug trials for it since 2013, and FDA has 2 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 41
  • Trials authorized in Canada: 34
  • FDA orphan approvals: 2
  • EU medicines: 0

Recruiting now

Newest posted first, of 41 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 12

Phase 2 12 of 23

Phase 1 or earlier 12

How its trials ended

262 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 46 whose ending is known, 28% met their primary endpoint, 17% missed it and 54% stopped early.

  • Completed, result not reported12849%
  • Ongoing5019%
  • Status unknown3815%
  • Met its primary endpoint135%
  • Stopped: lack of efficacy93%
  • Stopped: other or unclear93%
  • Missed its primary endpoint83%
  • Stopped: sponsor or business decision31%
  • Stopped: safety21%
  • Stopped: enrollment or feasibility21%

Trials authorized in Canada

The 10 newest of 34; search them all in Canada trials
Jun 3, 2026A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pridopidine in participants with Huntington’s disease (HD)Pridopidine (PL101)Prilenia Therapeutics B.V.Pending
May 5, 2026A phase 2/3 randomized, double blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety and efficacy of SKY-0515 in participants…SKY-0515Skyhawk Therapeutics, Inc.Ongoing
Feb 3, 2026A randomized, placebo-controlled, double-blind phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s…Votoplam (PTC518, HTT227)Novartis PharmaceuticalsOngoing
Oct 17, 2025A phase I, 2-part study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of intrathecally administered…RG6496 (RO7764733)RocheOngoing
Jul 18, 2024A randomized, double-blind, placebo-controlled study, to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intrathecally…ALN-HTT02Alnylam PharmaceuticalsOngoing
Jul 2, 2024A phase 2b, double-blind, randomized extension study to evaluate the long-term safety and efficacy of votoplam in participants with Huntington's diseaseVotoplam (HTT227, PTC518)Novartis PharmaceuticalsOngoing
Dec 18, 2023Long-term study to evaluate safety and tolerability of valbenazine in patients with chorea associated with Huntington disease in canadaValbenazineNeurocrine BiosciencesOngoing
Feb 16, 2023A phase 3, multicenter, open-label safety study to evaluate the long-term safety and tolerability of SAGE-718 in participants with Huntington's diseaseSAGE-718Sage TherapeuticsClosed
Dec 15, 2022A phase II, randomized, double-blind, placebo-controlled, dose-finding study to investigate the safety, biomarkers, and efficacy of tominersen in individuals…Tominersen (RO7234292)RocheOngoing
Nov 3, 2022A phase 2a, randomized, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of PTC518 in subjects with Huntington's diseasePTC518PTC TherapeuticsClosed

FDA orphan designations

Approved first, then open designations, newest first
Apr 30, 2024IngrezzaTreatment of adults with chorea associated with Huntington's diseaseNeurocrine Biosciences Inc.Approved
Aug 18, 2023IngrezzaTreatment of adults with chorea associated with Huntington's diseaseNeurocrine Biosciences Inc.Approved
Feb 11, 20192,4-dinitrophenolTreatment of Huntington diseaseMitochon Pharmaceuticals, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.